Name: William Soliman: LLY Retatrutide Raises the Bar in Weight Loss
Uploaded: 2026-05-27T14:24:32.028-05:00
Duration: 7 min 47 s
Description: Eli Lilly (LLY) leads in weight-loss drugs as retatrutide shows strong results. William Soliman highlights competition from Amgen (AMGN) and potential upside in Structure Therapeutics (GPCR), Viking Therapeutics (VKTX), and Altimmune (ALT).

Morning Movers

Opening Bell With Nicole Petallides

Morning Trade Live

Trading 360

Fast Market

Next Gen Investing

The Watch List

Market On Close

Market Overtime

Inside the Mind of a Trader

Your First Trade

The Wrap

Liz Ann Live

Schwab 2026 Outlook

Market Matters with Marley Kayden

<p>“Opening Bell with Nicole Petallides" is Schwab Network’s flagship new morning show—broadcast live from the floor of the New York Stock Exchange—and built from the ground up to serve the active trader, the tactical investor, and the market-curious viewer who wants more than just headlines.</p>

Daily insights for every investor

Schwab Network's Newsletters

<p>Eli Lilly (LLY) leads in weight-loss drugs as retatrutide shows strong results. William Soliman highlights competition from Amgen (AMGN) and potential upside in Structure Therapeutics (GPCR), Viking Therapeutics (VKTX), and Altimmune (ALT).</p>

William Soliman: LLY Retatrutide Raises the Bar in Weight Loss

Market News